Table 3.
Gestational ages and outcomes in patients with NARDS.a
| Characteristics and outcomes | Gestational ages (weeks, n) |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| <28 (31) | 28-29 + 6 (69) | 30-31 + 6 (93) | 32-33 + 6 (107) | 34-36 + 6 (213) | 37-38 + 6 (242) | 39-40 + 6 (205) | ≥41 (45) | ||
| Surfactant (yes, %) | 28 (90.3) | 56 (81.2) | 73 (78.5) | 77 (72.0) | 142 (66.7) | 163 (67.4) | 136 (66.3) | 26 (57.8) | |
| RDS (yes, %) | 17 (54.8) | 37 (53.6) | 51 (54.8) | 45 (42.1) | 59 (27.7) | 42 (17.4) | 41 (20.0) | 11 (24.4) | |
| NARDS | Mild | 14 (45.2) | 43 (62.3) | 50 (53.8) | 65 (60.7) | 115 (54.0) | 135 (55.8) | 103 (50.3) | 12 (26.7) |
| Moderate | 6 (19.4) | 14 (20.3) | 31 (33.3) | 17 (15.9) | 67 (31.5) | 65 (26.8) | 62 (30.2) | 24 (53.3) | |
| Severe | 11 (35.4) | 12 (17.4) | 12 (12.9) | 25 (23.4) | 31 (14.5) | 42 (17.4) | 40 (19.5) | 9 (20.0) | |
| LOS (yes, %) | 7 (22.6) | 11 (15.9) | 10 (10.8) | 13 (12.1) | 17 (8.0) | 20 (8.3) | 11 (5.4) | 4 (8.9) | |
| Air leak (yes, %) | 1 (3.3) | 7 (10.1) | 9 (9.7) | 8 (7.5) | 25 (11.7) | 34 (14.0) | 27 (13.1) | 8 (17.8) | |
| PH (yes, %) | 9 (29.0) | 9 (13.0) | 17 (18.2) | 13 (12.1) | 25 (21.7) | 35 (14.4) | 34 (16.6) | 11 (24.4) | |
| hsPDA (yes, %) | 19 (61.3) | 25 (36.2) | 35 (37.6) | 41 (38.3) | 90 (42.2) | 91 (37.6) | 75 (36.6) | 17 (37.8) | |
| PDA Closure after Ibuprofen | 7 (22.6) | 13 (18.8) | 19 (20.4) | 19 (17.8) | 34 (16.0) | 36 (14.9) | 16 (7.8) | 8 (17.8) | |
| PPHN (yes, %) | 7 (22.6) | 8 (11.6) | 20 (21.5) | 22 (20.6) | 53 (24.9) | 70 (28.9) | 67 (32.7) | 14 (31.1) | |
| IVH (yes, %) | 19 (61.3) | 32 (46.4) | 46 (49.5) | 31 (29.0) | 54 (25.4) | 39 (16.1) | 38 (18.5) | 8 (17.8) | |
| >2nd | 6 (19.4) | 11 (15.9) | 5 (5.4) | 4 (3.7) | 2 (0.9) | 1 (0.4) | 4 (2.0) | 0 (0) | |
| ROP (yes, %) | 15 (48.4) | 14 (20.2) | 12 (12.9) | 4 (3.7) | 9 (4.2) | 6 (2.4) | 5 (2.4) | 3 (6.7) | |
| ≥2 stage | 10 (32.3) | 5 (7.2) | 5 (5.4) | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | |
| NEC (yes, %) | 7 (22.6) | 12 (17.4) | 13 (14.0) | 3 (2.8) | 7 (3.3) | 10 (4.1) | 5 (2.4) | 4 (8.9) | |
| ≥2nd | 5 (16.1) | 6 (8.7) | 4 (4.3) | 1 (0.9) | 1 (0.5) | 1 (0.4) | 0 (0.0) | 0 (0) | |
| Total death (yes, %) | 12 (38.7) | 13 (18.8) | 16 (17.2) | 20 (18.7) | 15 (7.0) | 20 (8.2) | 21 (10.2) | 9 (20.0) | |
| Total BPD and/or death (yes, %) | 30 (96.8) | 43 (62.3) | 34 (36.6) | 28 (26.2) | 18 (8.4) | 24 (9.9) | 26 (12.7) | 10 (22.2) | |
| BPD (yes, %) | 24 (77.4) | 31 (44.9) | 21 (22.6) | 10 (9.3) | 4 (1.9) | 6 (2.4) | 6 (2.9) | 2 (4.4) | |
| Mild | 10 (32.3) | 21 (30.4) | 15 (16.1) | 4 (3.7) | 2 (0.9) | 4 (1.7) | 2 (0.9) | 1 (2.2) | |
| Moderate | 8 (25.8) | 3 (4.3) | 4 (4.3) | 3 (2.8) | 1 (0.5) | 0 (0) | 2 (0.9) | 0 (0) | |
| Severe | 6 (19.4) | 7 (10.1) | 2 (2.1) | 3 (2.8) | 1 (0.5) | 2 (0.8) | 2 (0.9) | 1 (2.2) | |
a
NARDS, neonatal acute respiratory distress syndrome; RDS, respiratory distress syndrome; LOS, late onset sepsis; PH, pulmonary hemorrhage; hsPDA, haemodynamically significant patent ductusarteriosus; PPHN, persistent pulmonary hypertension of newborn; IVH, intraventricular hemorrhage; ROP, retinopathy of prematurity; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia.